rs756881285
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_001282225.2(ADA2):c.144del(p.Arg49GlyfsTer4) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000378 in 1,613,160 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.000033 ( 0 hom., cov: 31)
Exomes 𝑓: 0.000038 ( 0 hom. )
Consequence
ADA2
NM_001282225.2 frameshift
NM_001282225.2 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: -0.668
Genes affected
ADA2 (HGNC:1839): (adenosine deaminase 2) This gene encodes a member of a subfamily of the adenosine deaminase protein family. The encoded protein is one of two adenosine deaminases found in humans, which regulate levels of the signaling molecule, adenosine. The encoded protein is secreted from monocytes undergoing differentiation and may regulate cell proliferation and differentiation. This gene may be responsible for some of the phenotypic features associated with cat eye syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 22-17209533-GC-G is Pathogenic according to our data. Variant chr22-17209533-GC-G is described in ClinVar as [Pathogenic]. Clinvar id is 640066.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr22-17209533-GC-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ADA2 | NM_001282225.2 | c.144del | p.Arg49GlyfsTer4 | frameshift_variant | 2/10 | ENST00000399837.8 | NP_001269154.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ADA2 | ENST00000399837.8 | c.144del | p.Arg49GlyfsTer4 | frameshift_variant | 2/10 | 1 | NM_001282225.2 | ENSP00000382731 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 151912Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
5
AN:
151912
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000319 AC: 8AN: 250912Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135722
GnomAD3 exomes
AF:
AC:
8
AN:
250912
Hom.:
AF XY:
AC XY:
3
AN XY:
135722
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000383 AC: 56AN: 1461248Hom.: 0 Cov.: 34 AF XY: 0.0000358 AC XY: 26AN XY: 726954
GnomAD4 exome
AF:
AC:
56
AN:
1461248
Hom.:
Cov.:
34
AF XY:
AC XY:
26
AN XY:
726954
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000329 AC: 5AN: 151912Hom.: 0 Cov.: 31 AF XY: 0.0000135 AC XY: 1AN XY: 74188
GnomAD4 genome
AF:
AC:
5
AN:
151912
Hom.:
Cov.:
31
AF XY:
AC XY:
1
AN XY:
74188
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Vasculitis due to ADA2 deficiency Pathogenic:2
Pathogenic, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | May 02, 2023 | The heterozygous p.Arg49GlyfsTer4 variant in ADA2 was identified by our study, in the compound heterozygous state with a likely pathogenic variant (ClinVar Variation ID: 624611), in one individual with vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome. Trio exome analysis revealed that this variant was in trans with a likely pathogenic variant (ClinVar Variation ID: 624611). The p.Arg49GlyfsTer4 variant in ADA2 has been previously reported in 4 unrelated individuals with vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome (PMID: 32909274, PMID: 35804211, PMID: 28522451, PMID: 27059682) and segregated with disease in 2 affected relatives from one family (PMID: 35804211), but has been identified in 0.007% (3/41374) of African/African American chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs756881285). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. Of these 4 previously reported unrelated individuals (PMID: 32909274, PMID: 35804211, PMID: 28522451, PMID: 27059682), one was a homozygote (PMID: 35804211) and two were compound heterozygotes who carried pathogenic or likely pathogenic variants in trans (PMID: 27059682, ClinVar Variation ID: 1407177; PMID: 28522451, ClinVar Variation ID 189342), which increases the likelihood that the p.Arg49GlyfsTer4 variant is pathogenic. This variant has also been reported in ClinVar (Variation ID: 640066) and has been interpreted as pathogenic by Invitae and Fulgent Genetics. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 49 and leads to a premature termination codon 4 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the ADA2 gene is strongly associated to autosomal recessive vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome. ACMG/AMP Criteria applied: PVS1_Strong, PM2_Supporting, PM3_Strong (Richards 2015). - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 20, 2024 | This sequence change creates a premature translational stop signal (p.Arg49Glyfs*4) in the ADA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ADA2 are known to be pathogenic (PMID: 24552284, 24552285). This variant is present in population databases (rs780731346, gnomAD 0.006%). This premature translational stop signal has been observed in individual(s) with polyarteritis nodosa or symptoms consistent with polyarteritis nodosa (PMID: 27059682, 28522451). This variant is also known as c.138/144delG. ClinVar contains an entry for this variant (Variation ID: 640066). For these reasons, this variant has been classified as Pathogenic. - |
Sneddon syndrome;C3887654:Vasculitis due to ADA2 deficiency Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Nov 19, 2021 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at